Bridgebio Pharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
BridgeBio Pharma, Inc. reports significant commercial uptake for Attruby and positive Phase 3 clinical trial results for multiple pipeline candidates, despite continued net losses.
NASDAQ
10-K: BridgeBio Pharma Reports Positive 2024 Results, Highlights Attruby Approval and Pipeline Progress
BridgeBio Pharma's 2024 10-K filing highlights the FDA approval of Attruby, its commercial launch, and advancements in its clinical pipeline.
NASDAQ
BridgeBio Pharma's 2023 10-K filing highlights the company's progress in developing transformative medicines for genetic diseases and cancers, while navigating financial strategies and regulatory pathways.